Treating Obstructive Sleep Apnea using cannabinoid-based drugs

Therapix Biosciences Ltd, have announced that the first subject was enrolled for its Phase IIa, a sponsor-initiated clinical trial for Obstructive Sleep Apnea…

Therapix Biosciences Ltd a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, have announced that the first subject was enrolled for its Phase IIa, sponsor-initiated clinical trial using the Company’s cannabinoid-based technology THX-110 for Obstructive Sleep Apnea (OSA), at Assuta Medical Center, the largest private hospital network in Israel.

The OSA Phase IIa proof-of-concept trial, titled “Examining the Efficacy of a Therapeutic Combination of Dronabinol (Pharma-grade ∆9-tetrahydracannabinol) and Palmitoylethanolamide (PEA) for

...read more at https://www.europeanpharmaceuticalreview.com/news/76266/sleep-apnea-cannabinoid/

Leave a Reply